• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

How to: ECOFFs—the why, the how, and the don'ts of EUCAST epidemiological cutoff values. CMI 2022.

How to: ECOFFs—the why, the how, and the don'ts of EUCAST epidemiological cutoff values Identifying the MIC wild-type distribution and its delineation of species targeted for receiving antimicrobial agent breakpoints is an important first step for determining clinical breakpoints. Having the main…

Get to know more

SOP 9 updated

SOP 9: Procedure for establishing zone diameterbreakpoints and quality control criteria for newantimicrobial agents , has been updated from 9.3 to 9.4. This SOP describes the necessary interaction between EUCAST, the EUCAST Development Laboratory (EDL) and when required, pharmaceutical companies to…

Get to know more

Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)

Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST) VetCAST is a EUCAST subcommittee formed in 2015 todeal with all aspects of antimicrobial susceptibility testing of bacterial pathogens of animal origin and animal bacteria with zoonotic potential. The subcommittee operates as…

Get to know more

Publications and presentations

Publications and presentations En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach. P-L Toutain et al. Frontiers in Microbiology, December 2017. Go to publication Population pharmacokinetics of…

Get to know more

Dosing in children

The European Society for Pediatric Infectious Disease ( ESPID ) has accepted an invitation from EUCAST to discuss dosing of antibiotics in children with specific reference to the EUCAST Dosing Table ( https://www.eucast.org/clinical_breakpoints/ ). EUCAST breakpoints, for both susceptible…

Get to know more

Resistance Detection

Resistance Detection Successful treatment of infectious diseases relies on knowledge and understanding of when antimicrobial resistance is an expected phenotype of the organism, and when resistance to antimicrobial agents may develop. The following documents provide up-to-date advice on how to…

Get to know more

SOPs

EUCAST SOPs SOP 1.5 Setting breakpoints for new antimicrobial agents (9 May, 2025) Previous versions 1.4 ; 1.3 ; 1.2 ; 1.1 SOP 2.5 Harmonising breakpoints for existing antimicrobial agents (12 May, 2025) Previous versions: 2.4 ; 2.3 ; 2.2 ; 2.1 SOP 3.4 Review and revision of breakpoints (6 May,…

Get to know more

What agents to test and which to avoid!

Occasionally colleagues request information from EUCAST on what agents to test and which to avoid . EUCAST has hitherto refrained from giving firm advice simply because national traditions, availability and cost of agents, and guidelines vary to the extent where a general prescriptive advice becomes…

Get to know more

Breakpoint tables for 2021 published

The EUCAST breakpoint tables for bacteria 2021 published.

Get to know more

Antifungal breakpoints and ECOFFs and QC tables updated.

Antifungal breakpoints and ECOFFs and QC tables updated.

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here